Skip to content

CareMaps-AI® Embryo Selection

CareMaps-AI® uses advanced imaging and AI to select the best embryos, improving your IVF success rates.

What is CareMaps-AI®?

CareMaps-AI is our unique embryo assessment and selection tool, we developed after decades of extensive research and testing. CareMaps-AI uses AI to select embryos with the highest chance of becoming a baby. 

Award-winning technology 

Care Fertility’s research is widely published, and our latest award-winning development uses AI to analyse embryo development from fertilisation right up to the point of embryo transfer. 

How was Caremaps-AI® developed? 

Care Fertility scientists collated almost half a billion images, from over 60,000 embryos, using time-lapse incubators and trained AI to assess them accurately and automatically. This information was then supplied to our own algorithm and compared to thousands of transferred embryos where we know a baby was born – allowing the machine to compare and predict the viability of the embryos. 

Could CareMaps-AI® be right for me?

Caremaps-AI® time-lapse embryo imaging is an additional procedure available to all our IVF patients. It is a non-invasive technique which is used to make our routine embryo selection process even more effective. Thousands of babies have been born following treatment where Caremaps-AI® was used.

Our award-winning Caremaps-AI combines advanced technology with expert insight, helping our labs to assess and select the best embryos to give the quickest and best possible outcomes for our patients. It's our own innovation, driving success at Care Fertility.

Benefits of Caremaps-AI®

This screening test can identify the presence of the Annexin A5 gene. If the gene is present in either the sperm or the egg provider, then there is at least a 50% chance it will be present in the embryo. 

Higher birth rates

Caremaps-AI has proven higher birth rates than standard methods, as Caremaps-AI® gives better embryo selection, allowing embryologists to see which embryos have the best chance of producing a baby.

Elevating embryo selection

Cell division timings and embryo development patterns are recorded using time-lapse images. 
Powered by AI to enable the very best embryo selection, combined with the best closed incubation environment and 12 years of timelapse experience, all delivered by some of the world’s best embryologists. 

Precise embryo selection Our scientists are world-leaders in time-lapse technology, and our Caremaps-AI® technique helps us to more reliably select the highest quality embryos, allowing us to see exactly what the chance of each embryo becoming a baby is.
Better than the human eye Embryo assessment using Machine Learning, when trained on large high-quality data, is more accurate and consistent than the assessments made by humans.
Removes any human subjectivity It is estimated that an embryologist with 10 years’ training and experience may have experience from assessing approximately 10,000 embryos over a decade. Caremaps-AI® was trained using over 60,000 embryos and almost half a billion images of those embryos.
Non-invasive treatment add-on This technology is safe and non-invasive. It assesses images of embryos which have already been collected and incubated.

Is Caremaps-AI® effective?

Caremaps (1)-1

We believe it is important that you have all the information you need before you decide to have treatment. We also recommend that you read the information on the Human Fertilisation and Embryology Authority (HFEA) website regarding add-ons and how the ratings were decided, before making a decision. 

Although the HFEA have rated time-lapse imaging ‘black’, the research evidence available is variable, due to the different approaches and types of time lapse devices used. The HFEA acknowledge this on their website. 

The rating does not consider specific algorithms like Caremaps-AI, for which there is insufficient published evidence available. However, in our hands, Caremaps-AI has been demonstrated to be better than standard methods and effective at: 

  • Predicting live birth 
  • Ensuring more accurate confirmation of fertilisation 
  • Providing more detailed information to our patients 

It is important to consider though that Caremaps-AI® combines time-lapse imaging with the use of Care Fertility’s unique embryo ranking model. Care Fertility’s own data from a study published in 2017 of more than 23,000 treatment cycles showed a highly significant increase in births when Caremaps-AI® was used to select embryos for patients aged younger than 38 using their own eggs.  

A paper published by Care Fertility in 2019 showed that Caremaps-AI® is superior for selecting embryos most likely to result in a birth than standard selection methods. 

 

HFEA rating

The independent regulator of fertility treatment, the (HFEA), has developed a new rating system and provides information about treatments that are offered on top of your routine fertility treatment – known as treatment add-ons. Their add-on ratings are based on published evidence, which the HFEA deems to be of suitable quality and quantity.  
 
For each add-on, ratings are provided for treatment outcomes, and for patient populations, for which this evidence was available at the time. 

The HFEA has given 'time-lapse imaging and incubation' a black rating because they consider it to have no benefit for most patients. 

118

 

Other fertility treatments